Entrust Clinical Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,307,949	339
2024	Research	$156,566	75
2023	Research	$652,893	43
2022	Research	$1,070,273	43
2021	Research	$3,444	8

Breakdown

Who paid Research payments · program years 2021–2025

Pfizer Inc. $1,321,769 82 payments
Boehringer Ingelheim International GmbH $1,149,164 304 payments
Incyte Corporation $559,619 111 payments
Novartis Pharmaceuticals Corporation $106,182 1 payment
GlaxoSmithKline, LLC. $44,515 8 payments
AstraZeneca Pharmaceuticals LP $9,860 1 payment
Eli Lilly and Company $15 1 payment

Studies the money was for Research payments · program years 2021–2025

A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $1,055,467 247 payments
A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $920,869 20 payments
A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $356,236 16 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $208,554 11 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $199,735 15 payments
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis $110,948 59 payments
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $106,182 1 payment
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $89,836 54 payments
17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $44,515 8 payments
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis $23,012 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.